Taurine: The comeback of a neutraceutical in the prevention of retinal degenerations

Progress in Retinal and Eye Research

Volumn 41, Issue , 2014, Pages 44-63

  Froger, Nicolas ^a,b   Moutsimilli, Larissa ^a,b   Cadetti, Lucia ^a,b   Jammoul, Firas ^a,b   Wang, Qing Ping ^a,b   Fan, Yichao ^a,b   Gaucher, David ^a,b,c,i   Rosolen, Serge G ^a,b   Neveux, Nathalie ^g,h   Cynober, Luc ^g,h   Sahel, José Alain ^a,b,c,d,e,f   Picaud, Serge ^a,b,e  

^a INSTITUT DE LA VISION   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^f French School of Political Science   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ HÔPITAL CIVIL   (France)

Author keywords

Diabetic retinopathy; Glaucoma; Neuroprotection; Nutrition; Retinal degeneration; Retinal ganglion cells; Retinitis pigmentosa; Taurine; Taurine transporter

Indexed keywords

CALCIUM; TAURINE; TAURINE TRANSPORTER; VIGABATRIN; NEUROPROTECTIVE AGENT;

ALCOHOLISM; ANEMIA; ANTIOXIDANT ACTIVITY; BORDERLINE HYPERTENSION; CAPILLARY ENDOTHELIAL CELL; CELL SURVIVAL; CONGESTIVE HEART FAILURE; CYSTIC FIBROSIS; DIABETIC RETINOPATHY; DIET SUPPLEMENTATION; EXCITOTOXICITY; GENE DELETION; GLAUCOMA; HUMAN; MYOTONIC DYSTROPHY; NEUROPROTECTION; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHOTORECEPTOR; PHOTOTOXICITY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA DISEASE; RETINA GANGLION CELL; RETINITIS PIGMENTOSA; REVIEW; ANIMAL; CHEMISTRY; PHYSIOLOGY; RETINAL DEGENERATION;

ANIMALS; HUMANS; NEUROPROTECTIVE AGENTS; RETINAL DEGENERATION; TAURINE;

EID: 84926262465     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2014.03.001     Document Type: Review

References (266)

1. Ackermann D., Heinsen H.A. Uber die physiologische Wirkung des Asterubins and anderer, zum Teil neu dargestellter swhwefelhaltiger Guanidiniderivate. Hope Sezylers Z. Physiol. Chem. 1935, 235.
2. Aguirre G.D. Retinal degeneration associated with the feeding of dog foods to cats. J. Am. Veterinary Med. Assoc. 1978, 172:791-796.
3. Aiello L.P., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris F.L., Klein R. Diabetic retinopathy. Diabetes Care 1998, 21:143-156.
4. Airaksinen E.M., Sihvola P., Airaksinen M.M., Sihvola M., Tuovinen E. Uptake of taurine by platelets in retinitis pigmentosa. Lancet 1979, 1:474-475.
5. Airaksinen E.M., Airaksinen M.M., Sihvola P., Marnela K.M. Decrease in the uptake and concentration of taurine in blood platelets of retinitis pigmentosa patients. Metab. Pediatr. Ophthalmol. 1981, 5:45-48.
6. Albinana E., Sacristan S., Martin del Rio R., Solis J.M., Hernandez-Guijo J.M. Modulation of calcium channels by taurine acting via a metabotropic-like glycine receptor. Cell Mol. Neurobiol. 2010, 30:1225-1233.
7. Albrecht J., Schousboe A. Taurine interaction with neurotransmitter receptors in the CNS: an update. Neurochem Res. 2005, 30:1615-1621.
8. Alvarado-Vasquez N., Zamudio P., Ceron E., Vanda B., Zenteno E., Carvajal-Sandoval G. Effect of glycine in streptozotocin-induced diabetic rats. Comp. Biochem Physiol. C. Toxicol. Pharmacol. 2003, 134:521-527.
9. Ament M.E., Geggel H.S., Heckenlively J.R., Martin D.A., Kopple J. Taurine supplementation in infants receiving long-term total parenteral nutrition. J. Am. Coll. Nutr. 1986, 5:127-135.
10. Anderson M.G., Smith R.S., Hawes N.L., Zabaleta A., Chang B., Wiggs J.L., John S.W. Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat. Genet. 2002, 30:81-85.
11. Anderson C.M., Howard A., Walters J.R., Ganapathy V., Thwaites D.T. Taurine uptake across the human intestinal brush-border membrane is via two transporters: H+-coupled PAT1 (SLC36A1) and Na+- and Cl(-)-dependent TauT (SLC6A6). J. Physiology 2009, 587:731-744.
12. Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy. NEngl. J. Med. 2012, 366:1227-1239.
13. Araie M., Crowston J., Iwase A., Tomidokoro A., Leung C., Zeitz O., Vingris A., Schmetterer L., Ritch R., Kook M., Erlich R., Gherghel D., Graham S., Pillunat L., Aung T., Hafez A., Liu J., Harris A. Clinical Relevance of Ocular Blood Flow (OBF) Measurements Including Effects of General Medications or Specific Glaucoma Treatment 2009, Kugler Publications, Amsterdam, the Netherlands.
14. Arnault E., Barrau C., Nanteau C., Gondouin P., Bigot K., Vienot F., Gutman E., Fontaine V., Villette T., Cohen-Tannoudji D., Sahel J.A., Picaud S. Phototoxic action spectrum on a retinal pigment epithelium model of age-related macular degeneration exposed to sunlight normalized conditions. PLoS One 2013, 8:e71398.
15. Arndt C.F., Derambure P., Defoort-Dhellemmes S., Hache J.C. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999, 52:1201-1205.
16. Arshinoff S.A., McCulloch J.C., Macrae W., Stein A.N., Marliss E.B. Amino acids in retinitis pigmentosa. Br. J. Ophthalmol. 1981, 65:626-630.
17. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J. 1988, 256:251-255.
18. Askwith T., Zeng W., Eggo M.C., Stevens M.J. Oxidative stress and dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E620-E628.
19. Asnaghi V., Gerhardinger C., Hoehn T., Adeboje A., Lorenzi M. Arole for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003, 52:506-511.
20. Balse E., Tessier L.H., Forster V., Roux M.J., Sahel J.A., Picaud S. Glycine receptors in a population of adult mammalian cones. J. Physiol. 2006, 571:391-401.
21. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest. 1998, 102:783-791.
22. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
23. Beatty S., Koh H., Phil M., Henson D., Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2000, 45:115-134.
24. Beetsch J.W., Olson J.E. Taurine synthesis and cysteine metabolism in cultured rat astrocytes: effects of hyperosmotic exposure. Am. J. Physiol. 1998, 274:C866-C874.
25. Behar-Cohen F., Martinsons C., Vienot F., Zissis G., Barlier-Salsi A., Cesarini J.P., Enouf O., Garcia M., Picaud S., Attia D. Light-emitting diodes (LED) for domestic lighting: any risks for the eye?. Prog. Retin Eye Res. 2011, 30:239-257.
26. Ben-Menachem E., Dulac O., Chiron C. Vigabatrin. Epilepsy: a Comprehensive Textbook 2008, 1683-1693. Lippincott Willams & Wilkins, Philadelphia. J.J. Engel, T.A. Pedley (Eds.).
27. Benini G., Marconcini C., Wirth A., Montagnoli G. Is taurine a marker for retinitis pigmentosa?. Ophthalmologica 1988, 197:130-135.
28. Berson E.L., Hayes K.C., Rabin A.R., Schmidt S.Y., Watson G. Retinal degeneration in cats fed casein. II. Supplementation with methionine, cysteine, or taurine. Investig. Ophthalmol. 1976, 15:52-58.
29. Bianchi L., Lari R., Anichini R., De Bellis A., Berti A., Napoli Z., Seghieri G., Franconi F. Taurine transporter gene expression in peripheral mononuclear blood cells of type 2 diabetic patients. Amino Acids 2012, 42:2267-2274.
30. Braun M., Ramracheya R., Bengtsson M., Clark A., Walker J.N., Johnson P.R., Rorsman P. Gamma-aminobutyric acid (GABA) is an autocrine excitatory transmitter in human pancreatic beta-cells. Diabetes 2010, 59:1694-1701.
31. Brons C., Spohr C., Storgaard H., Dyerberg J., Vaag A. Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. Eur. J. Clin. Nutr. 2004, 58:1239-1247.
32. 2+-dependent pathways in retinal third-order neurons. J. Biomed. Sci. 2010, 17(Suppl.1):S5.
33. Bulley S., Liu Y., Ripps H., Shen W. Taurine activates delayed rectifier KV channels via a metabotropic pathway in retinal neurons. J. Physiol. 2013, 591:123-132.
34. Buncic J.R., Westall C.A., Panton C.M., Munn J.R., MacKeen L.D., Logan W.J. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 2004, 111:1935-1942.
35. Butler W.H., Ford G.P., Newberne J.W. Astudy of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol. Pathol. 1987, 15:143-148.
36. Cai J., Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye (Lond) 2002, 16:242-260.
37. Cellini M., Strobbe E., Gizzi C., Campos E.C. ET-1 plasma levels and ocular blood flow in retinitis pigmentosa. Can. J. Physiol. Pharmacol. 2010, 88:630-635.
38. Chauncey K.B., Tenner T.E., Lombardini J.B., Jones B.G., Brooks M.L., Warner R.D., Davis R.L., Ragain R.M. The effect of taurine supplementation on patients with type 2 diabetes mellitus. Adv. Exp. Med. Biol. 2003, 526:91-96.
39. Chen W.Q., Jin H., Nguyen M., Carr J., Lee Y.J., Hsu C.C., Faiman M.D., Schloss J.V., Wu J.Y. Role of taurine in regulation of intracellular calcium level and neuroprotective function in cultured neurons. J. Neurosci. Res. 2001, 66:612-619.
40. Chen K., Zhang Q., Wang J., Liu F., Mi M., Xu H., Chen F., Zeng K. Taurine protects transformed rat retinal ganglion cells from hypoxia-induced apoptosis by preventing mitochondrial dysfunction. Brain Res. 2009, 1279:131-138.
41. Cherif H., Reusens B., Dahri S., Remacle C., Hoet J.J. Stimulatory effects of taurine on insulin secretion by fetal rat islets cultured invitro. J. Endocrinol. 1996, 151:501-506.
42. Chiron C., Dumas C., Jambaque I., Mumford J., Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997, 26:389-395.
43. Choi D.W. Ionic dependence of glutamate neurotoxicity. J. Neurosci. 1987, 7:369-379.
44. Choi S.S., Zawadzki R.J., Lim M.C., Brandt J.D., Keltner J.L., Doble N., Werner J.S. Evidence of outer retinal changes in glaucoma patients as revealed by ultrahigh-resolution invivo retinal imaging. Br. J. Ophthalmol. 2011, 95:131-141.
45. Chrysostomou V., Rezania F., Trounce I.A., Crowston J.G. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr. Opin. Pharmacol. 2013, 13:12-15.
46. Cocker S.E., Lake N. Effects of dark maintenance on retinal biochemistry and function during taurine depletion in the adult rat. Vis. Neurosci. 1989, 3:33-38.
47. Costa B.L., Fawcett R., Li G.Y., Safa R., Osborne N.N. Orally administered epigallocatechin gallate attenuates light-induced photoreceptor damage. Brain Res. Bull. 2008, 76:412-423.
48. Cozzi R., Ricordy R., Bartolini F., Ramadori L., Perticone P., De Salvia R. Taurine and ellagic acid: two differently-acting natural antioxidants. Environ. Mol. Mutagen 1995, 26:248-254.
49. Cuttitta C.M., Guariglia S.R., Idrissi A.E., L'Amoreaux W.J. Taurine's effects on the neuroendocrine functions of pancreatic beta cells. Adv. Exp. Med. Biol. 2013, 775:299-310.
50. Daneshvar H., Racette L., Coupland S.G., Kertes P.J., Guberman A., Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999, 106:1792-1798.
51. Das J., Sil P.C. Taurine ameliorates alloxan-induced diabetic renal injury, oxidative stress-related signaling pathways and apoptosis in rats. Amino Acids 2012, 43:1509-1523.
52. Das J., Vasan V., Sil P.C. Taurine exerts hypoglycemic effect in alloxan-induced diabetic rats, improves insulin-mediated glucose transport signaling pathway in heart and ameliorates cardiac oxidative stress and apoptosis. Toxicol. Appl. Pharmacol. 2012, 258:296-308.
53. Dawson R., Liu S., Eppler B., Patterson T. Effects of dietary taurine supplementation or deprivation in aged male Fischer 344 rats. Mech. Ageing Dev. 1999, 107:73-91.
54. Dawson R., Liu S., Jung B., Messina S., Eppler B. Effects of high salt diets and taurine on the development of hypertension in the stroke-prone spontaneously hypertensive rat. Amino Acids 2000, 19:643-665.
55. De la Puerta C., Arrieta F.J., Balsa J.A., Botella-Carretero J.I., Zamarron I., Vazquez C. Taurine and glucose metabolism: a review. Nutr. Hosp. 2010, 25:910-919.
56. De Luca G., Calpona P.R., Caponetti A., Romano G., Di Benedetto A., Cucinotta D., Di Giorgio R.M. Taurine and osmoregulation: platelet taurine content, uptake, and release in type 2 diabetic patients. Metabolism 2001, 50:60-64.
57. del Olmo-Aguado S., Manso A.G., Osborne N.N. Light might directly affect retinal ganglion cell mitochondria to potentially influence function. Photochem Photobiol. 2012, 88:1346-1355.
58. Demarcay H. Ueber die Natur der Galle. Ann. Pharm. 1838, 27:270-291.
59. Di Leo M.A., Ghirlanda G., Gentiloni Silveri N., Giardina B., Franconi F., Santini S.A. Potential therapeutic effect of antioxidants in experimental diabetic retina: a comparison between chronic taurine and vitamin E plus selenium supplementations. Free Radic. Res. 2003, 37:323-330.
60. Di Leo M.A., Santini S.A., Silveri N.G., Giardina B., Franconi F., Ghirlanda G. Long-term taurine supplementation reduces mortality rate in streptozotocin-induced diabetic rats. Amino Acids 2004, 27:187-191.
61. Dominy J., Eller S., Dawson R. Building biosynthetic schools: reviewing compartmentation of CNS taurine synthesis. Neurochem. Res. 2004, 29:97-103.
62. Duboc A., Hanoteau N., Simonutti M., Rudolf G., Nehlig A., Sahel J.A., Picaud S. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann. Neurol. 2004, 55:695-705.
63. Dupre S., De Marco C. Activity of some animal tissues on the oxidation of cysteamine to hypotaurine in the presence of sulphide. Ital. J. Biochem. 1964, 13:386-390.
64. Eke T., Talbot J.F., Lawden M.C. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997, 314:180-181.
65. El Idrissi A. Taurine increases mitochondrial buffering of calcium: role in neuroprotection. Amino Acids 2008, 34:321-328.
66. El Idrissi A., Trenkner E. Growth factors and taurine protect against excitotoxicity by stabilizing calcium homeostasis and energy metabolism. J. Neurosci. 1999, 19:9459-9468.
67. El Idrissi A., Trenkner E. Taurine regulates mitochondrial calcium homeostasis. Adv. Exp. Med. Biol. 2003, 526:527-536.
68. El Idrissi A., Boukarrou L., L'Amoreaux W. Taurine supplementation and pancreatic remodeling. Adv. Exp. Med. Biol. 2009, 643:353-358.
69. El-Sherbeny A., Naggar H., Miyauchi S., Ola M.S., Maddox D.M., Martin P.M., Ganapathy V., Smith S.B. Osmoregulation of taurine transporter function and expression in retinal pigment epithelial, ganglion, and muller cells. Investig. Ophthalmol. Vis. Sci. 2004, 45:694-701.
70. Falsini B., Anselmi G.M., Marangoni D., D'Esposito F., Fadda A., Di Renzo A., Campos E.C., Riva C.E. Subfoveal choroidal blood flow and central retinal function in retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 2011, 52:1064-1069.
71. Flora S.J., Pande M., Bhadauria S., Kannan G.M. Combined administration of taurine and meso 2,3-dimercaptosuccinic acid in the treatment of chronic lead intoxication in rats. Hum. Exp. Toxicol. 2004, 23:157-166.
72. Foos T.M., Wu J.Y. The role of taurine in the central nervous system and the modulation of intracellular calcium homeostasis. Neurochem Res. 2002, 27:21-26.
73. Franconi F., Bennardini F., Mattana A., Miceli M., Ciuti M., Mian M., Gironi A., Anichini R., Seghieri G. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am. J. Clin. Nutr. 1995, 61:1115-1119.
74. Franconi F., Miceli M., Fazzini A., Seghieri G., Caputo S., DiLeo M.A., Lepore D., Ghirlanda G. Taurine and diabetes. Humans and experimental models. Adv. Exp. Med. Biol. 1996, 403:579-582.
75. Frisen L., Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol. Scand. 2003, 81:466-473.
76. Froger N., Cadetti L., Lorach H., Martins J., Bemelmans A.P., Dubus E., Degardin J., Pain D., Forster V., Chicaud L., Ivkovic I., Simonutti M., Fouquet S., Jammoul F., Leveillard T., Benosman R., Sahel J.A., Picaud S. Taurine provides neuroprotection against retinal ganglion cell degeneration. PLoS One 2012, 7:e42017.
77. Froger N., Jammoul F., Gaucher D., Cadetti L., Lorach H., Degardin J., Pain D., Dubus E., Forster V., Ivkovic I., Simonutti M., Sahel J.A., Picaud S. Taurine is a crucial factor to preserve retinal ganglion cell survival. Adv. Exp. Med. Biol. 2013, 775:69-83.
78. Fuchs C., Forster V., Balse E., Sahel J.A., Picaud S., Tessier L.H. Retinal-cell-conditioned medium prevents TNF-alpha-induced apoptosis of purified ganglion cells. Investig. Ophthalmol. Vis. Sci. 2005, 46:2983-2991.
79. Garcia-Ayuso D., Salinas-Navarro M., Agudo M., Cuenca N., Pinilla I., Vidal-Sanz M., Villegas-Perez M.P. Retinal ganglion cell numbers and delayed retinal ganglion cell death in the P23H rat retina. Exp. Eye Res. 2010, 91:800-810.
80. Gaucher D., Chiappore J.A., Paques M., Simonutti M., Boitard C., Sahel J.A., Massin P., Picaud S. Microglial changes occur without neural cell death in diabetic retinopathy. Vis. Res. 2007, 47:612-623.
81. Gaucher D., Arnault E., Husson Z., Froger N., Dubus E., Gondouin P., Dherbecourt D., Degardin J., Simonutti M., Fouquet S., Benahmed M.A., Elbayed K., Namer I.J., Massin P., Sahel J.A., Picaud S. Taurine deficiency damages retinal neurones: cone photoreceptors and retinal ganglion cells. Amino Acids 2012, 43:1979-1993.
82. Gaull G.E. Taurine in pediatric nutrition: review and update. Pediatrics 1989, 83:433-442.
83. Geggel H.S., Ament M.E., Heckenlively J.R., Martin D.A., Kopple J.D. Nutritional requirement for taurine in patients receiving long-term parenteral nutrition. N. Engl. J. Med. 1985, 312:142-146.
84. Grant S.M., Heel R.C. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991, 41:889-926.
85. Grunwald J.E., Maguire A.M., Dupont J. Retinal hemodynamics in retinitis pigmentosa. Am. J. Ophthalmol. 1996, 122:502-508.
86. Gupta K., Mathur R.L. Distribution of taurine in the crystalline lens of vertebrate species and in cataractogenesis. Exp. Eye Res. 1983, 37:379-384.
87. Haber C.A., Lam T.K., Yu Z., Gupta N., Goh T., Bogdanovic E., Giacca A., Fantus I.G. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance invivo: possible role of oxidative stress. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E744-E753.
88. Hamaguchi T., Azuma J., Schaffer S. Interaction of taurine with methionine: inhibition of myocardial phospholipid methyltransferase. J. Cardiovasc Pharmacol. 1991, 18:224-230.
89. Hansen S.H. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab. Res. Rev. 2001, 17:330-346.
90. Hansen S.H. Taurine homeostasis and its importance for physiological functions. Metabolic and Therapeutic Aspects of Amino-acids in Clinical Nutrition 2004, 739-747. CRC Press, Boca Raton. L. Cynober (Ed.).
91. Harada N., Ninomiya C., Osako Y., Morishima M., Mawatari K., Takahashi A., Nakaya Y. Taurine alters respiratory gas exchange and nutrient metabolism in type 2 diabetic rats. Obes. Res. 2004, 12:1077-1084.
92. Hayes K.C., Sturman J.A. Taurine deficiency: a rationale for taurine depletion. Adv. Exp. Med. Biol. 1981, 139:79-87.
93. Hayes K.C., Sturman J.A. Taurine in metabolism. Annu Rev. Nutr. 1981, 1:401-425.
94. Hayes K.C., Carey R.E., Schmidt S.Y. Retinal degeneration associated with taurine deficiency in the cat. Science 1975, 188:949-951.
95. Hayes K.C., Stephan Z.F., Sturman J.A. Growth depression in taurine-depleted infant monkeys. J. Nutr. 1980, 110:2058-2064.
96. Heinamaki A.A., Muhonen A.S., Piha R.S. Taurine and other free amino acids in the retina, vitreous, lens, iris-ciliary body, and cornea of the rat eye. Neurochem Res. 1986, 11:535-542.
97. Heinz E., Walsh P.M. Exchange diffusion, transport, and intracellular level of amino acids in Ehrlich carcinoma cells. J. Biol. Chem. 1958, 233:1488-1493.
98. Heller-Stilb B., van Roeyen C., Rascher K., Hartwig H.G., Huth A., Seeliger M.W., Warskulat U., Haussinger D. Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. Faseb J. 2002, 16:231-233.
99. Hillenkamp J., Hussain A.A., Jackson T.L., Cunningham J.R., Marshall J. Taurine uptake by human retinal pigment epithelium: implications for the transport of small solutes between the choroid and the outer retina. Investig. Ophthalmol. Vis. Sci. 2004, 45:4529-4534.
100. Hilton E.J., Cubbidge R.P., Hosking S.L., Betts T., Comaish I.F. Patients treated with vigabatrin exhibit central visual function loss. Epilepsia 2002, 43:1351-1359.
101. Humayun M.S., Prince M., de Juan E., Barron Y., Moskowitz M., Klock I.B., Milam A.H. Morphometric analysis of the extramacular retina from postmortem eyes with retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 1999, 40:143-148.
102. Hunter J.J., Morgan J.I., Merigan W.H., Sliney D.H., Sparrow J.R., Williams D.R. The susceptibility of the retina to photochemical damage from visible light. Prog. Retin Eye Res. 2012, 31:28-42.
103. Huxtable R.J. Taurine and the oxidative metabolism of cystein. Biochemistry of Sulfur 1986, 121-198. Plenum Press, New York. R.J. Huxtable (Ed.).
104. Huxtable R.J. Taurine in the central nervous system and the mammalian actions of taurine. Prog. Neurobiol. 1989, 32:471-533.
105. Huxtable R.J. Physiological actions of taurine. Physiol. Rev. 1992, 72:101-163.
106. Huxtable R.J., Lippincott S.E. Comparative metabolism and taurine-depleting effects of guanidinoethanesulfonate in cats, mice, and guinea pigs. Arch. Biochem Biophys. 1981, 210:698-709.
107. Huxtable R.J., Laird H.E., Lippincott S.E. The transport of taurine in the heart and the rapid depletion of tissue taurine content by guanidinoethyl sulfonate. J. Pharmacol. Exp. Ther. 1979, 211:465-471.
108. Ida S., Nishimura C., Ueno E., Kuriyama K. Alteration of metabolism of retinal taurine following prolonged light and dark adaptation: a quantitative comparison with gamma-aminobutyric acid (GABA). J. Neurosci. Res. 1981, 6:497-509.
109. Ikeda H. Effects of taurine on alcohol withdrawal. Lancet 1977, 2:509.
110. Imaki H., Moretz R., Wisniewski H., Neuringer M., Sturman J. Retinal degeneration in 3-month-old rhesus monkey infants fed a taurine-free human infant formula. J. Neurosci. Res. 1987, 18:602-614.
111. Imaki H., Messing J., Sturman J.A. Extensive taurine depletion and retinal degeneration in cats treated with beta-alanine for 40 weeks. Adv. Exp. Med. Biol. 1998, 442:449-460.
112. Ito T., Kimura Y., Uozumi Y., Takai M., Muraoka S., Matsuda T., Ueki K., Yoshiyama M., Ikawa M., Okabe M., Schaffer S.W., Fujio Y., Azuma J. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J. Mol. Cell. Cardiol. 2008, 44:927-937.
113. Ito T., Schaffer S.W., Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids 2012, 42:1529-1539.
114. Izumi Y., Ishikawa M., Benz A.M., Izumi M., Zorumski C.F., Thio L.L. Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia 2004, 45:1043-1048.
115. Jacobsen J.G., Smith L.H. Biochemistry and physiology of taurine and taurine derivatives. Physiol. Rev. 1968, 48:424-511.
116. Jammoul F., Wang Q., Nabbout R., Coriat C., Duboc A., Simonutti M., Dubus E., Craft C.M., Ye W., Collins S.D., Dulac O., Chiron C., Sahel J.A., Picaud S. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann. Neurol. 2009, 65:98-107.
117. Jammoul F., Degardin J., Pain D., Gondouin P., Simonutti M., Dubus E., Caplette R., Fouquet S., Craft C.M., Sahel J.A., Picaud S. Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol. Cell. Neurosci. 2010, 43:414-421.
118. John S.W., Smith R.S., Savinova O.V., Hawes N.L., Chang B., Turnbull D., Davisson M., Roderick T.H., Heckenlively J.R. Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Investig. Ophthalmol. Vis. Sci. 1998, 39:951-962.
119. Johnson M.A., Krauss G.L., Miller N.R., Medura M., Paul S.R. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000, 55:40-45.
120. Jones S.M., Palmer M.J. Activation of the tonic GABAC receptor current in retinal bipolar cell terminals by nonvesicular GABA release. J. Neurophysiol. 2009, 102:691-699.
121. Jones D.P., Miller L.A., Chesney R.W. The relative roles of external taurine concentration and medium osmolality in the regulation of taurine transport in LLC-PK1 and MDCK cells. Pediatr. Res. 1995, 37:227-232.
122. Kawai, Unger R.H. Effects of gamma-aminobutyric acid on insulin, glucagon, and somatostatin release from isolated perfused dog pancreas. Endocrinology 1983, 113:111-113.
123. Kendell K.R., Quigley H.A., Kerrigan L.A., Pease M.E., Quigley E.N. Primary open-angle glaucoma is not associated with photoreceptor loss. Investig. Ophthalmol. Vis. Sci. 1995, 36:200-205.
124. Kilic F., Bhardwaj R., Caulfeild J., Trevithick J.R. Modelling cortical cataractogenesis 22: is invitro reduction of damage in model diabetic rat cataract by taurine due to its antioxidant activity?. Exp. Eye Res. 1999, 69:291-300.
125. Kim K.S., Oh da H., Kim J.Y., Lee B.G., You J.S., Chang K.J., Chung H.J., Yoo M.C., Yang H.I., Kang J.H., Hwang Y.C., Ahn K.J., Chung H.Y., Jeong I.K. Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes. Exp. Mol. Med. 2012, 44:665-673.
126. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
127. Kishi M., Ohkuma S., Kimori M., Kuriyama K. Characteristics of taurine transport system and its developmental pattern in mouse cerebral cortical neurons in primary culture. Biochim. Biophys. Acta 1988, 939:615-623.
128. Kolomiets B., Dubus E., Simonutti M., Rosolen S., Sahel J.A., Picaud S. Late histological and functional changes in the P23H rat retina after photoreceptor loss. Neurobiol. Dis. 2010, 38:47-58.
129. Konieczka K., Flammer A.J., Todorova M., Meyer P., Flammer J. Retinitis pigmentosa and ocular blood flow. Epma J. 2012, 3:17.
130. Krauss G.L., Johnson M.A., Miller N.R. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998, 50:614-618.
131. Kubota T., Schlotzer-Schrehardt U.M., Naumann G.O., Kohno T., Inomata H. The ultrastructure of parapapillary chorioretinal atrophy in eyes with secondary angle closure glaucoma. Graefe's Arch Clin Exp Ophthalmol 1996, 234:351-358.
132. Kulakowski E.C., Maturo J. Hypoglycemic properties of taurine: not mediated by enhanced insulin release. Biochem. Pharmacol. 1984, 33:2835-2838.
133. L'Amoreaux W.J., Cuttitta C., Santora A., Blaize J.F., Tachjadi J., El Idrissi A. Taurine regulates insulin release from pancreatic beta cell lines. J. Biomed. Sci. 2010, 17(Suppl.1):S11.
134. Laidlaw S.A., Shultz T.D., Cecchino J.T., Kopple J.D. Plasma and urine taurine levels in vegans. Am. J. Clin. Nutr. 1988, 47:660-663.
135. Lake N., Malik N. Retinal morphology in rats treated with a taurine transport antagonist. Exp. Eye Res. 1987, 44:331-346.
136. Lake N., Malik N., De Marte L. Taurine depletion leads to loss of rat optic nerve axons. Vis. Res. 1988, 28:1071-1076.
137. Lampson W.G., Kramer J.H., Schaffer S.W. Potentiation of the actions of insulin by taurine. Can. J. Physiol. Pharmacol. 1983, 61:457-463.
138. Lascaratos G., Ji D., Wood J.P., Osborne N.N. Visible light affects mitochondrial function and induces neuronal death in retinal cell cultures. Vis. Res. 2007, 47:1191-1201.
139. Lawden M.C., Eke T., Degg C., Harding G.F., Wild J.M. Visual field defects associated with vigabatrin therapy. J. Neurol. Neurosurg. Psychiatry 1999, 67:716-722.
140. Lazarewicz J.W., Noremberg K., Lehmann A., Hamberger A. Effects of taurine on calcium binding and accumulation in rabbit hippocampal and cortical synaptosomes. Neurochem Int. 1985, 7:421-427.
141. Leon A., Levick W.R., Sarossy M.G. Lesion topography and new histological features in feline taurine deficiency retinopathy. Exp. Eye Res. 1995, 61:731-741.
142. Li M., Reynolds C.M., Sloboda D.M., Gray C., Vickers M.H. Effects of taurine supplementation on hepatic markers of inflammation and lipid metabolism in mothers and offspring in the setting of maternal obesity. PLoS One 2013, 8:e76961.
143. Liu Q.R., Lopez-Corcuera B., Nelson H., Mandiyan S., Nelson N. Cloning and expression of a cDNA encoding the transporter of taurine and beta-alanine in mouse brain. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:12145-12149.
144. Lombardini J.B. Taurine: retinal function. Brain Res. Brain Res. Rev. 1991, 16:151-169.
145. Lombardini J.B., Singer T.P., Boyer P.D. Cystein oxygenase. II. Studies on the mechanism of the reaction with 18 oxygen. J. Biol. Chem. 1969, 244:1172-1175.
146. Loriette C., Chatagner F. Cysteine oxidase and cysteine sulfinic acid decarboxylase in developing rat liver. Experientia 1978, 34:981-982.
147. Macaione S., Ruggeri P., De Luca F., Tucci G. Free amino acids in developing rat retina. J. Neurochem. 1974, 22:887-891.
148. Macaione S., Tucci G., De Luca G., Di Girorgio R.M. Subcellular distribution of taurine and cysteine sulphinate decarboxylase activity in ox retina. J. Neurochem. 1976, 27:1411-1415.
149. Madl J.E., McIlnay T.R., Powell C.C., Gionfriddo J.R. Depletion of taurine and glutamate from damaged photoreceptors in the retinas of dogs with primary glaucoma. Am. J. Vet. Res. 2005, 66:791-799.
150. Magenta A., Greco S., Gaetano C., Martelli F. Oxidative stress and microRNAs in vascular diseases. Int. J. Mol. Sci. 2013, 14:17319-17346.
151. Malone J.I., Benford S.A., Malone J. Taurine prevents galactose-induced cataracts. J. Diabetes Complicat. 1993, 7:44-48.
152. Marc R.E., Jones B.W., Watt C.B., Strettoi E. Neural remodeling in retinal degeneration. Prog. Retin Eye Res. 2003, 22:607-655.
153. Martin P.M., Roon P., Van Ells T.K., Ganapathy V., Smith S.B. Death of retinal neurons in streptozotocin-induced diabetic mice. Investig. Ophthalmol. Vis. Sci. 2004, 45:3330-3336.
154. Matuk Y. Retinitis pigmentosa and retinal degeneration in animals: a review. Can. J. Biochem Cell. Biol. 1984, 62:535-546.
155. Maturo J., Kulakowski E.C. Insulin-like activity of taurine. Adv. Exp. Med. Biol. 1987, 217:217-226.
156. Maturo J., Kulakowski E.C. Taurine binding to the purified insulin receptor. Biochem. Pharmacol. 1988, 37:3755-3760.
157. Merheb M., Daher R.T., Nasrallah M., Sabra R., Ziyadeh F.N., Barada K. Taurine intestinal absorption and renal excretion test in diabetic patients: a pilot study. Diabetes Care 2007, 30:2652-2654.
158. Milam A.H., Li Z.Y., Fariss R.N. Histopathology of the human retina in retinitis pigmentosa. Prog. Retin Eye Res. 1998, 17:175-205.
159. Milea D., Cassoux N., LeHoang P. Blindness in a strict vegan. NEngl. J. Med. 2000, 342:897-898.
160. Militante J.D., Lombardini J.B. Treatment of hypertension with oral taurine: experimental and clinical studies. Amino Acids 2002, 23:381-393.
161. Miller N.R., Johnson M.A., Paul S.R., Girkin C.A., Perry J.D., Endres M., Krauss G.L. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999, 53:2082-2087.
162. Mochizuki H., Takido J., Oda H., Yokogoshi H. Improving effect of dietary taurine on marked hypercholesterolemia induced by a high-cholesterol diet in streptozotocin-induced diabetic rats. Biosci. Biotechnol. Biochem. 1999, 63:1984-1987.
163. Moloney M.A., Casey R.G., O'Donnell D.H., Fitzgerald P., Thompson C., Bouchier-Hayes D.J. Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diab Vasc. Dis. Res. 2010, 7:300-310.
164. Munck L.K., Munck B.G. Distinction between chloride-dependent transport systems for taurine and beta-alanine in rabbit ileum. Am. J. Physiol. 1992, 262:G609-G615.
165. Munck L.K., Munck B.G. Chloride-dependent intestinal transport of imino and beta-amino acids in the guinea pig and rat. Am. J. Physiol. 1994, 266:R997-R1007.
166. Nadal-Nicolas F.M., Jimenez-Lopez M., Sobrado-Calvo P., Nieto-Lopez L., Canovas-Martinez I., Salinas-Navarro M., Vidal-Sanz M., Agudo M. Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas. Investig. Ophthalmol. Vis. Sci. 2009, 50:3860-3868.
167. Nakashio S., Nakanishi T., Koshikawa T., Nishihara T., Ichikawa T., Kondo M. Identification of taurine occurring sporulating cells of Bacillus subtilis. Microbios 1982, 33:73-80.
168. Nakaya Y., Minami A., Harada N., Sakamoto S., Niwa Y., Ohnaka M. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am. J. Clin. Nutr. 2000, 71:54-58.
169. Nishimura C., Ida S., Kuriyama K. Taurine biosynthesis in frog retina: effects of light and dark adaptations. J. Neurosci. Res. 1983, 9:59-67.
170. Nonaka H., Tsujino T., Watari Y., Emoto N., Yokoyama M. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine: amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation 2001, 104:1165-1170.
171. Obrosova I.G., Minchenko A.G., Marinescu V., Fathallah L., Kennedy A., Stockert C.M., Frank R.N., Stevens M.J. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001, 44:1102-1110.
172. Okaya Y. Refinement of the crystal structure of taurine, 2-aminoethylsulfonic acid. An example of computer-controlled experimentation. Acta Chrystallogr. 1966, 21:726-735.
173. Oraedu A.C., Voaden M.J., Marshall J. Photochemical damage in the albino rat retina: morphological changes and endogenous amino acids. J. Neurochem 1980, 35:1361-1369.
174. Orr H.T., Cohen A.I., Carter J.A. The levels of free taurine, glutamate, glycine and gamma-amino butyric acid during the postnatal development of the normal and dystrophic retina of the mouse. Exp. Eye Res. 1976, 23:377-384.
175. Osborne N.N. Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog. Brain Res. 2008, 173:339-352.
176. Osborne N.N., Li G.Y., Ji D., Mortiboys H.J., Jackson S. Light affects mitochondria to cause apoptosis to cultured cells: possible relevance to ganglion cell death in certain optic neuropathies. J. Neurochem. 2008, 105:2013-2028.
177. Osborne N.N., Kamalden T.A., Majid A.S., del Olmo-Aguado S., Manso A.G., Ji D. Light effects on mitochondrial photosensitizers in relation to retinal degeneration. Neurochem Res. 2010, 35:2027-2034.
178. Panda S., Jonas J.B. Decreased photoreceptor count in human eyes with secondary angle-closure glaucoma. Investig. Ophthalmol. Vis. Sci. 1992, 33:2532-2536.
179. Park S.H., Park J.W., Park S.J., Kim K.Y., Chung J.W., Chun M.H., Oh S.J. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 2003, 46:1260-1268.
180. Pasantes-Morales H. Taurine function in excitable tissues: the retina as a model. Retinal Transmitters and Modulators: Models for the Brain 1985, 33-62. CRC Press, Boca Raton, Florida. W.W. Moroan (Ed.).
181. Pasantes-Morales H., Cruz C. Taurine and hypotaurine inhibit light-induced lipid peroxidation and protect rod outer segment structure. Brain Res. 1985, 330:154-157.
182. Pasantes-Morales H., Cruz C. Taurine: a physiological stabilizer of photoreceptor membranes. Prog. Clin. Biol. Res. 1985, 179:371-381.
183. Pasantes-Morales H., Klethi J., Ledig M., Mandel P. Free amino acids of chicken and rat retina. Brain Res. 1972, 41:494-497.
184. Pasantes-Morales H., Klethi J., Ledig M., Mandel P. Influence of light and dark on the free amino acid pattern of the developing chick retina. Brain Res. 1973, 57:59-65.
185. Pasantes-Morales H., Urban P.F., Klethi J., Mandel P. Light stimulated release of [35 S]Taurine from chicken retina. Brain Res. 1973, 51:375-378.
186. Pasantes-Morales H., Ademe R.M., Quesada O. Protective effect of taurine on the light-induced disruption of isolated frog rod outer segments. J. Neurosci. Res. 1981, 6:337-348.
187. Pasantes-Morales H., Quesada O., Carabez A., Huxtable R.J. Effects of the taurine transport antagonist, guanidinoethane sulfonate, and beta-alanine on the morphology of rat retina. J. Neurosci. Res. 1983, 9:135-143.
188. Pasantes-Morales H., Quiroz H., Quesada O. Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. Metab. Brain Dis. 2002, 17:183-197.
189. Penn J.S., Li S., Naash M.I. Ambient hypoxia reverses retinal vascular attenuation in a transgenic mouse model of autosomal dominant retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 2000, 41:4007-4013.
190. Piez K.A., Eagle H. The free amino acid pool of cultured human cells. J. Biol. Chem. 1958, 231:533-545.
191. Ponjavic V., Granse L., Kjellstrom S., Andreasson S., Bruun A. Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin. Doc. Ophthalmol. 2004, 108:125-133.
192. Purchas R.W., Rutherfurd S.M., Pearce P.D., Vather R., Wilkinson B.H. Concentrations in beef and lamb of taurine, carnosine, coenzyme Q(10), and creatine. Meat Sci. 2004, 66:629-637.
193. Quesada O., Picones A., Pasantes-Morales H. Effect of light deprivation on the ERG responses of taurine-deficient rats. Exp. Eye Res. 1988, 46:13-20.
194. Rana S.K., Sanders T.A. Taurine concentrations in the diet, plasma, urine and breast milk of vegans compared with omnivores. Br. J. Nutr. 1986, 56:17-27.
195. Rapp L.M., Thum L.A., Anderson R.E. Synergism between environmental lighting and taurine depletion in causing photoreceptor cell degeneration. Exp. Eye Res. 1988, 46:229-238.
196. Rascher K., Servos G., Berthold G., Hartwig H.G., Warskulat U., Heller-Stilb B., Haussinger D. Light deprivation slows but does not prevent the loss of photoreceptors in taurine transporter knockout mice. Vis. Res. 2004, 44:2091-2100.
197. Ravindran J., Blumbergs P., Crompton J., Pietris G., Waddy H. Visual field loss associated with vigabatrin: pathological correlations. J. Neurol. Neurosurg. Psychiatry 2001, 70:787-789.
198. Reccia R., Pignalosa B., Grasso A., Campanella G. Taurine treatment in retinitis pigmentosa. Acta Neurol. (Napoli) 1980, 2:132-136.
199. Reddy D.V. Distribution of free amino acids and related compounds in ocular fluids, lens, and plasma of various mammalian species. Investig. Ophthalmol. 1967, 6:478-483.
200. Reddy D.V. Studies on intraocular transport of taurine. I. Accumulation in rabbit ciliary body-iris preparation invitro. Biochim. Biophys. Acta 1968, 158:246-254.
201. Redmond H.P., Wang J.H., Bouchier-Hayes D. Taurine attenuates nitric oxide- and reactive oxygen intermediate-dependent hepatocyte injury. Arch. Surg. 1996, 131:1280-1287. discussion 1287-1288.
202. Remy A., Henry S., Tappaz M. Specific antiserum and monoclonal antibodies against the taurine biosynthesis enzyme cysteine sulfinate decarboxylase: identity of brain and liver enzyme. J. Neurochem 1990, 54:870-879.
203. Ripps H., Shen W. Review: taurine: a "very essential" amino acid. Mol. Vis. 2012, 18:2673-2686.
204. Rosolen S.G., Neveux N., Sahel J.A., Picaud S., Froger N. Evaluation of the taurine concentrations in dog plasma and aqueous humour: a pilot study. Adv. Exp. Med. Biol. 2013, 775:145-154.
205. Rozanowska M.B. Light-induced damage to the retina: current understanding of the mechanisms and unresolved questions: a symposium-in-print. Photochem Photobiol. 2012, 88:1303-1308.
206. Ruether K., Pung T., Kellner U., Schmitz B., Hartmann C., Seeliger M. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch. Ophthalmol. 1998, 116:817-819.
207. Russian study Taurin in combined treatment of metabolic syndrome and diabetes mellitus. Ter. Arkh 2011, 83:31-36.
208. Satin L.S., Kinard T.A. Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: what messages do acetylcholine, glutamate, and GABA transmit?. Endocrine 1998, 8:213-223.
209. Schaffer S.W., Azuma J. Myocardial physiological effects of taurine and their significance. Taurine: Nutrition Value and Mechanisms of Action 1992, 105-120. Plenum Press, New York. J.B. Lombardini, S.W. Schaffer, J. Azuma (Eds.).
210. Schaffer S.W., Azuma J., Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can. J. Physiol. Pharmacol. 2009, 87:91-99.
211. Schmidt S.Y. Taurine in retinas of taurine-deficient cats and RCS rats. The Effects of Taurine on Excitable Tissues 1981, 177-186. Spectrum Publications, New York. S.W. Schaffer, S.I. Baskin, J.J. Kocsis (Eds.).
212. Schmidt S.Y., Aguirre G.D. Reductions in taurine secondary to photoreceptor loss in Irish setters with rod-cone dysplasia. Investig. Ophthalmol. Vis. Sci. 1985, 26:679-683.
213. Schmidt S.Y., Berson E.L. Taurine uptake in isolated retinas of normal rats and rats with hereditary retinal degeneration. Exp. Eye Res. 1978, 27:191-198.
214. Schmidt S.Y., Berson E.L., Hayes K.C. Retinal degeneration in the taurine-deficient cat. Trans. Sect. Ophthalmol. Am. Acad. Ophthalmol. Otolaryngol. 1976, 81:OP687-OP693.
215. Schmidt S.Y., Berson E.L., Watson G., Huang C. Retinal degeneration in cats fed casein. III. Taurine deficiency and ERG amplitudes. Investig. Ophthalmol. Vis. Sci. 1977, 16:673-678.
216. Seghieri G., Tesi F., Bianchi L., Loizzo A., Saccomanni G., Ghirlanda G., Anichini R., Franconi F. Taurine in women with a history of gestational diabetes. Diabetes Res. Clin. Pract. 2007, 76:187-192.
217. Seki M., Lipton S.A. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog. Brain Res. 2008, 173:495-510.
218. Shao A., Hathcock J.N. Risk assessment for the amino acids taurine, L-glutamine and L-arginine. Regul. Toxicol. Pharmacol. 2008, 50:376-399.
219. Shareef S.R., Garcia-Valenzuela E., Salierno A., Walsh J., Sharma S.C. Chronic ocular hypertension following episcleral venous occlusion in rats. Exp. Eye Res. 1995, 61:379-382.
220. Shioda R., Reinach P.S., Hisatsune T., Miyamoto Y. Osmosensitive taurine transporter expression and activity in human corneal epithelial cells. Investig. Ophthalmol. Vis. Sci. 2002, 43:2916-2922.
221. Smith K.E., Borden L.A., Wang C.H., Hartig P.R., Branchek T.A., Weinshank R.L. Cloning and expression of a high affinity taurine transporter from rat brain. Mol. Pharmacol. 1992, 42:563-569.
222. Spohr C., Brons C., Winther K., Dyerberg J., Vaag A. No effect of taurine on platelet aggregation in men with a predisposition to type 2 diabetes mellitus. Platelets 2005, 16:301-305.
223. Stadler K. Oxidative stress in diabetes. Adv. Exp. Med. Biol. 2012, 771:272-287.
224. Starr M.S., Voaden M.J. The uptake, metabolism and release of 14C-taurine by rat retina invitro. Vis. Res. 1972, 12:1261-1269.
225. Stevens M.J., Hosaka Y., Masterson J.A., Jones S.M., Thomas T.P., Larkin D.D. Downregulation of the human taurine transporter by glucose in cultured retinal pigment epithelial cells. Am. J. Physiol. 1999, 277:E760-E771.
226. Sturman J.A. Cysteinesulfinic acid decarboxylase activity in the mammalian nervous system: absence from axons. J. Neurochem 1981, 36:304-306.
227. Sturman J.A. Taurine in development. J. Nutr. 1988, 118:1169-1176.
228. Sturman J.A., Messing J.M., Rossi S.S., Hofmann A.F., Neuringer M.D. Tissue taurine content and conjugated bile acid composition of rhesus monkey infants fed a human infant soy-protein formula with or without taurine supplementation for 3 months. Neurochem Res. 1988, 13:311-316.
229. Tappaz M., Almarghini K., Legay F., Remy A. Taurine biosynthesis enzyme cysteine sulfinate decarboxylase (CSD) from brain: the long and tricky trail to identification. Neurochem Res. 1992, 17:849-859.
230. Tappia P.S., Thliveris J., Xu Y.J., Aroutiounova N., Dhalla N.S. Effects of amino acid supplementation on myocardial cell damage and cardiac function in diabetes. Exp. Clin. Cardiol. 2011, 16:e17-e22.
231. Tenner T.E., Zhang X.J., Lombardini J.B. Hypoglycemic effects of taurine in the alloxan-treated rabbit, a model for type 1 diabetes. Adv. Exp. Med. Biol. 2003, 526:97-104.
232. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin Eye Res. 2006, 25:490-513.
233. Thwaites D.T., McEwan G.T., Simmons N.L. The role of the proton electrochemical gradient in the transepithelial absorption of amino acids by human intestinal Caco-2 cell monolayers. J. Membr. Biol. 1995, 145:245-256.
234. Timbrell J.A., Seabra V., Waterfield C.J. The invivo and invitro protective properties of taurine. Gen. Pharmacol. 1995, 26:453-462.
235. Tokunaga H., Yoneda Y., Kuriyama K. Protective actions of taurine against streptozotocin-induced hyperglycemia. Biochem. Pharmacol. 1979, 28:2807-2811.
236. Tokunaga H., Yoneda Y., Kuriyama K. Streptozotocin-induced elevation of pancreatic taurine content and suppressive effect of taurine on insulin secretion. Eur. J. Pharmacol. 1983, 87:237-243.
237. Tomi M., Tajima A., Tachikawa M., Hosoya K.I. Function of taurine transporter (Slc6a6/TauT) as a GABA transporting protein and its relevance to GABA transport in rat retinal capillary endothelial cells. Biochim. Biophys. Acta 2008, 1778:2138-2142.
238. Trachtman H., Barbour R., Sturman J.A., Finberg L. Taurine and osmoregulation: taurine is a cerebral osmoprotective molecule in chronic hypernatremic dehydration. Pediatr. Res. 1988, 23:35-39.
239. Trachtman H., Futterweit S., Bienkowski R.S. Taurine prevents glucose-induced lipid peroxidation and increased collagen production in cultured rat mesangial cells. Biochem Biophys. Res. Commun. 1993, 191:759-765.
240. Trachtman H., Futterweit S., Maesaka J., Ma C., Valderrama E., Fuchs A., Tarectecan A.A., Rao P.S., Sturman J.A., Boles T.H., et al. Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats. Am. J. Physiol. 1995, 269:F429-F438.
241. Tumosa N. Eye disease and the older diabetic. Clin. Geriatr. Med. 2008, 24:515-527.
242. Uchida S., Sasaki S., Furukawa T., Hiraoka M., Imai T., Hirata Y., Marumo F. Molecular cloning of a chloride channel that is regulated by dehydration and expressed predominantly in kidney medulla. J. Biol. Chem. 1993, 268:3821-3824.
243. van der Torren K., Graniewski-Wijnands H.S., Polak B.C. Visual field and electrophysiological abnormalities due to vigabatrin. Doc. Ophthalmol. 2002, 104:181-188.
244. Velten I.M., Korth M., Horn F.K. The a-wave of the dark adapted electroretinogram in glaucomas: are photoreceptors affected?. Br. J. Ophthalmol. 2001, 85:397-402.
245. Vesce S., Kirk L., Nicholls D.G. Relationships between superoxide levels and delayed calcium deregulation in cultured cerebellar granule cells exposed continuously to glutamate. J. Neurochem 2004, 90:683-693.
246. Villegas-Perez M.P., Lawrence J.M., Vidal-Sanz M., Lavail M.M., Lund R.D. Ganglion cell loss in RCS rat retina: a result of compression of axons by contracting intraretinal vessels linked to the pigment epithelium. J. Comp. Neurol. 1998, 392:58-77.
247. Vinnakota S., Qian X., Egal H., Sarthy V., Sarkar H.K. Molecular characterization and in situ localization of a mouse retinal taurine transporter. J. Neurochem 1997, 69:2238-2250.
248. Vohra B.P., Hui X. Taurine protects against carbon tetrachloride toxicity in the cultured neurons and invivo. Arch. Physiol. Biochem 2001, 109:90-94.
249. Wang S., Villegas-Perez M.P., Vidal-Sanz M., Lund R.D. Progressive optic axon dystrophy and vascular changes in rd mice. Investig. Ophthalmol. Vis. Sci. 2000, 41:537-545.
250. Wang Q.P., Jammoul F., Duboc A., Gong J., Simonutti M., Dubus E., Craft C.M., Ye W., Sahel J.A., Picaud S. Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina. Eur. J. Neurosci. 2008, 27:2177-2187.
251. Westall C.A., Nobile R., Morong S., Buncic J.R., Logan W.J., Panton C.M. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc. Ophthalmol. 2003, 107:299-309.
252. Wild J.M., Robson C.R., Jones A.L., Cunliffe I.A., Smith P.E. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Investig. Ophthalmol. Vis. Sci. 2006, 47:917-924.
253. Winiarska K., Szymanski K., Gorniak P., Dudziak M., Bryla J. Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochimie 2009, 91:261-270.
254. Wood J.P., Lascaratos G., Bron A.J., Osborne N.N. The influence of visible light exposure on cultured RGC-5 cells. Mol. Vis. 2007, 14:334-344.
255. Wright C.E., Lin T.T., Lin Y.Y., Sturman J.A., Gaull G.E. Taurine scavenges oxidized chlorine in biological systems. Prog. Clin. Biol. Res. 1985, 179:137-147.
256. Wu H., Jin Y., Wei J., Jin H., Sha D., Wu J.Y. Mode of action of taurine as a neuroprotector. Brain Res. 2005, 1038:123-131.
257. Wu G., Yang J., Sun C., Luan X., Shi J., Hu J. Effect of taurine on alcoholic liver disease in rats. Amino Acids 2009, 36:457-464.
258. Yamaguchi K., Shigehisa S., Sakakibara S., Hosokawa Y., Ueda I. Cysteine metabolism invivo of vitamin B6-deficient rats. Biochim. Biophys. Acta 1975, 381:1-8.
259. Yamori Y., Nara Y., Ikeda K., Mizushima S. Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition?. Adv. Exp. Med. Biol. 1996, 403:623-629.
260. Yan M.H., Wang X., Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic. Biol. Med. 2013, 62:90-101.
261. Yau J.W., Rogers S.L., Kawasaki R., Lamoureux E.L., Kowalski J.W., Bek T., Chen S.J., Dekker J.M., Fletcher A., Grauslund J., Haffner S., Hamman R.F., Ikram M.K., Kayama T., Klein B.E., Klein R., Krishnaiah S., Mayurasakorn K., O'Hare J.P., Orchard T.J., Porta M., Rema M., Roy M.S., Sharma T., Shaw J., Taylor H., Tielsch J.M., Varma R., Wang J.J., Wang N., West S., Xu L., Yasuda M., Zhang X., Mitchell P., Wong T.Y. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012, 35:556-564.
262. Yildirim Z., Kilic N., Ozer C., Babul A., Take G., Erdogan D. Effects of taurine in cellular responses to oxidative stress in young and middle-aged rat liver. Ann. N. Y. Acad. Sci. 2007, 1100:553-561.
263. Yu X., Xu Z., Mi M., Xu H., Zhu J., Wei N., Chen K., Zhang Q., Zeng K., Wang J., Chen F., Tang Y. Dietary taurine supplementation ameliorates diabetic retinopathy via anti-excitotoxicity of glutamate in streptozotocin-induced Sprague-Dawley rats. Neurochem Res. 2008, 33:500-507.
264. Zeng K., Xu H., Mi M., Zhang Q., Zhang Y., Chen K., Chen F., Zhu J., Yu X. Dietary taurine supplementation prevents glial alterations in retina of diabetic rats. Neurochem Res. 2009, 34:244-254.
265. Zeng K., Xu H., Mi M., Chen K., Zhu J., Yi L., Zhang T., Zhang Q., Yu X. Effects of taurine on glial cells apoptosis and taurine transporter expression in retina under diabetic conditions. Neurochem Res. 2010, 35:1566-1574.
266. Zhao X.-H. Dietary protein, amino acids and their relation to health. Asia Pac. J. Clin. Nutr. 1994, 3:131-134.